Venus Remedies Ltd

₹ 1,634 4.99%

05 Jun - close price

venusremedies.com BSE: 526953 NSE: VENUSREM

About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer^[1]

Key Points

Business Overview:^[1]^[2]
VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 1040+ marketing authorizations globally, 135+ patents and 180+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE

Market Cap ₹ 2,184 Cr.
Current Price ₹ 1,634
High / Low ₹ 1,637 / 415
Stock P/E 22.0
Book Value ₹ 516
Dividend Yield 0.00 %
ROCE 20.2 %
ROE 15.5 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has delivered good profit growth of 26.4% CAGR over last 5 years

Cons

Stock is trading at 3.17 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 8.53% over past five years.
Company has a low return on equity of 10.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	149	99	170	131	175	106	170	172	197	137	193	180	259
	128	85	157	118	154	92	157	150	171	119	163	143	200
Operating Profit	21	13	13	13	21	14	13	23	25	18	30	37	59
OPM %	14%	14%	8%	10%	12%	13%	8%	13%	13%	13%	15%	20%	23%
	3	2	3	2	4	2	8	12	4	3	2	2	5
Interest	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Depreciation	8	7	6	6	6	6	6	5	4	6	6	6	7
Profit before tax	16	8	10	9	19	10	15	29	25	15	26	33	58
Tax %	53%	47%	45%	10%	36%	56%	37%	18%	40%	20%	25%	24%	25%
	8	4	5	8	13	4	9	24	15	12	19	25	43
EPS in Rs	5.64	3.25	4.08	6.13	9.36	3.33	6.93	18.01	11.06	8.75	14.39	18.64	32.51
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	443	392	375	355	299	316	511	574	534	570	631	769
	356	312	328	312	265	273	464	505	473	509	561	625
Operating Profit	87	80	47	44	34	43	47	69	62	61	70	144
OPM %	20%	20%	13%	12%	11%	14%	9%	12%	12%	11%	11%	19%
	1	1	1	1	-4	-5	41	8	10	11	31	11
Interest	41	37	34	35	25	13	13	-0	-0	-0	-0	-0
Depreciation	45	40	39	33	33	31	34	33	31	26	22	25
Profit before tax	2	3	-25	-23	-28	-6	41	45	40	47	79	131
Tax %	-123%	60%	-18%	13%	-4%	31%	-32%	-10%	28%	35%	34%	24%
	5	1	-20	-27	-27	-8	54	49	29	30	53	99
EPS in Rs	3.98	1.05	-16.40	-21.54	-21.97	-6.67	43.97	36.65	21.67	22.82	39.32	74.29
Dividend Payout %	-0%	-0%	-0%	-0%	-0%	-0%	-0%	-0%	-0%	-0%	-0%	-0%

Compounded Sales Growth
10 Years:	7%
5 Years:	9%
3 Years:	13%
TTM:	22%

Compounded Profit Growth
10 Years:	56%
5 Years:	26%
3 Years:	51%
TTM:	123%

Stock Price CAGR
10 Years:	35%
5 Years:	38%
3 Years:	94%
1 Year:	280%

Return on Equity
10 Years:	5%
5 Years:	10%
3 Years:	10%
Last Year:	16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	11	11	12	12	12	12	12	13	13	13	13	13
Reserves	455	433	382	356	329	320	388	436	465	495	576	676
	319	327	308	302	294	216	48	39	39	39	-0	12
	60	63	65	78	97	96	99	91	92	94	124	174
Total Liabilities	845	834	767	748	732	644	547	579	609	641	713	876
	426	434	389	370	347	271	244	225	200	203	214	215
CWIP	78	80	66	65	65	25	25	25	26	21	26	51
Investments	29	29	29	0	0	0	0	0	20	19	84	238
	312	291	283	314	320	348	277	329	363	398	388	372
Total Assets	845	834	767	748	732	644	547	579	609	641	713	876

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	67	42	62	52	44	78	132	41	28	35	83	151
	-67	3	-18	-11	-11	-5	56	-17	-51	-7	-76	-182
	-0	-46	-44	-40	-35	-72	-162	-9	-0	-0	-0	-1
Net Cash Flow	-1	-0	0	0	-2	1	26	15	-23	28	7	-32
Free Cash Flow	-1	-8	44	40	34	70	132	27	20	23	65	114
CFO/OP	77%	53%	131%	118%	127%	181%	282%	60%	46%	84%	140%	129%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	49	50	41	45	38	34	12	19	58	57	57	55
Inventory Days	189	210	230	242	283	282	130	121	123	122	98	122
Days Payable	35	36	50	48	67	70	74	48	53	54	67	104
Cash Conversion Cycle	203	223	220	239	254	246	67	93	129	126	88	73
Working Capital Days	54	73	52	23	-3	77	68	84	118	129	97	104
ROCE %	6%	5%	1%	2%	1%	3%	6%	10%	8%	9%	12%	20%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Global Presence (Countries)
Number

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx		x,xxx	xxx	xx,xxx
xxx	xxx	xxx	xxx		xxx	xxx	xxx	x,xxx	x,xxx
xxx	x,xxx	x,xxx	x,xxx	x,xxx			x,xxx	xx,xxx	xx,xxx
xxx	xxx		xxx		xxx	xxx	xxx	xxx	xxx
xxx.xx	xxx.xx	xxx.xx					xxx.xx	xx.xx	xxx.xx
	xx	xx		xx		xxx		xxx	xxx
							x	x	x
xx.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Stockist Network
Number

Total Marketing Authorizations (Cumulative)
Number

Hospital Reach
Number

Patents Granted (Cumulative)
Number

Annual Manufacturing Capacity (Injectables)
Million Units

New Product Approvals (Annual)
Number

Internal Product Rejections
Number

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
	0.98%	1.03%	1.59%	1.48%	1.06%	1.18%	1.11%	1.34%	2.25%	1.86%	2.25%	2.80%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.11%	0.75%	1.03%	1.20%
	57.26%	57.21%	56.65%	56.76%	57.17%	57.06%	57.13%	56.90%	55.89%	55.62%	54.95%	54.24%
No. of Shareholders	20,498	19,267	19,560	19,913	19,614	19,557	19,771	19,982	19,307	17,725	18,606	18,403

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	37.51%	37.51%	37.51%	35.89%	35.89%	40.81%	41.76%	41.76%	41.76%	41.76%
	0.48%	0.48%	0.04%	0.04%	0.04%	0.33%	1.00%	1.48%	1.34%	2.80%
	0.28%	0.45%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.20%
	61.73%	61.56%	62.43%	64.07%	64.07%	58.86%	57.26%	56.76%	56.90%	54.24%
No. of Shareholders	20,556	19,316	18,375	17,209	13,829	19,952	21,719	19,913	19,982	18,403

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Venus Remedies Ltd

Venus Remedies Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings